Advertisement
COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA)designed to deliver efficacy in migraine without the vasoconstrictor activityassociated with previous generations of migraine therapy. COL-144 selectivelytargets 5HT1F receptors expressed in the trigeminal nerve pathway. CoLucidcompleted a Phase II clinical trial last year examining the efficacy ofCOL-144 in the acute treatment of migraine after intravenous administration.The trial provided clear evidence of safe, effective alleviation of migrainepain and identified a range of doses that provided relief of migraine symptomsand were well tolerated. Based on these encouraging results, CoLucid isadvancing clinical development of COL-144 as a treatment for migraine by theoral route of administration.
Advertisement
As a part of the Series B financing, CoLucid also announced the additionof Richard Markham, partner at Care Capital, to the Board of Directors. Priorto joining Care Capital, Markham held several senior leadership positions inthe pharmaceutical industry, including CEO of Aventis Pharma, CEO of HoechstMarion Roussel and President, COO and Board member of Marion Merrell Dow. Inaddition, he served as President and COO of Merck.
"COL-144 is the first in a new class of migraine therapeutics andrepresents a paradigm shift in the treatment of migraine," said James White,Ph.D., President and CEO of CoLucid. "The continuing high level of support andenthusiasm from Care Capital and our initial investors will enable us tofurther advance this unique therapeutic and deliver safe and effective painrelief to a wider range of migraine patients."
In addition to COL-144, CoLucid's pipeline includes a conjugated stigmineplatform that has generated a series of preclinical candidates for thetreatment of sleep/wake disorders, chronic pain, Alzheimer's disease andanxiety/depression disorders. COL-204, the lead compound in the conjugatedstigmine program, is expected to enter clinical development in early 2009 forwake promotion.
About CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures toadvance innovative drug candidates with the potential to provide safe andeffective treatment for central nervous system (CNS) disorders. The company'spipeline includes COL-144, a novel treatment for migraine headache, and aconjugated stigmine platform that has generated a series of preclinicalcandidates for the treatment of sleep/wake disorders, chronic pain,Alzheimer's disease and psychiatric disorders. For more information, pleasevisit CoLucid at http://www.colucid.com.
About Care Capital
Care Capital is a life sciences venture capital firm based in Princeton,New Jersey. It manages approximately $500 million and is currently investingits third fund, Care Capital Investments III. The firm invests inbiotechnology and specialty pharmaceutical companies that are developingpharmaceutical assets and whose lead products have reached late-preclinical orearly clinical development. Its typical initial investment size is from $5 to$15 million. For more information, please visit http://www.carecapital.com.
About Pappas Ventures
Pappas Ventures is a Research Triangle Park, North Carolina-based venturecapital firm that invests nationally in the life science industry.
